Sector#Biotechnology - Therapeutics
- #Diseases of the blood and blood-forming organs - immune disorders
- #Diseases of the nervous system
- #Infectious and parasitic diseases
- #Musculoskeletal system and connective tissue
- #Neoplasms / cancer / oncology
- #Respiratory system
Sanofi R&D Belgium based in Ghent is as an end-to-end research and early development Center of Excellence and active in the discovery of NANOBODY® molecules, through the development of drugs up to their clinical proof-of-concept.
NANOBODY® molecules are proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. NANOBODY® technology is the next generation of antibody-derived biologics and have great potential. They are being developed for the treatment of a range of serious and life-threatening human diseases including hematology, inflammation, immune-oncology, oncology and rare diseases.
Latest newsMore news
Cerba Research & Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture
7 hours ago
Novalis Biotech invests in Rarity Bioscience's ultra sensitive genomics technology
1 day ago
Fat creates an ideal environment for metastatic breast tumors
1 day ago